Semaglutide vs Liraglutide
A comparison of Semaglutide and Liraglutide as GLP-1 receptor agonists, covering dosing cadence, evidence maturity, metabolic outcomes, and cardiovascular research.
A comparison of Semaglutide and Liraglutide as GLP-1 receptor agonists, covering dosing cadence, evidence maturity, metabolic outcomes, and cardiovascular research.
Overview
Semaglutide and Liraglutide are both GLP-1 receptor agonists with established clinical publication histories, but they differ in dosing cadence, pharmacokinetic profile, and the depth and breadth of the current evidence base. Semaglutide has largely displaced Liraglutide in metabolic research discussions due to its once-weekly administration and stronger published outcomes in multiple outcome areas.
Mechanism Comparison
Both compounds are GLP-1 receptor agonists working through the same primary signaling pathway — incretin-mediated insulin secretion, satiety signaling, gastric emptying effects, and glucagonostatic activity. The key structural difference is that Semaglutide has a longer fatty acid chain modification enabling weekly dosing, while Liraglutide requires daily administration due to its shorter effective half-life.
Dosing and Protocol Comparison
Liraglutide is studied at daily subcutaneous doses in the 0.6–3.0 mg range, while Semaglutide is studied at weekly doses starting at 0.25 mg and escalating to 0.5–2.0 mg in most published protocols. The once-weekly convenience of Semaglutide has made it the dominant comparison point in newer incretin research, and most current metabolic trial designs benchmark against Semaglutide rather than Liraglutide.
Evidence Comparison
Both compounds have robust human clinical trial evidence including cardiovascular outcome trials. Liraglutide demonstrated cardiovascular benefit in the LEADER trial, while Semaglutide showed comparable or stronger outcomes in SUSTAIN-6 and STEP trials. Semaglutide's evidence base has grown more rapidly in recent years, particularly in obesity research contexts.